Approach to dosing, monitoring, and toxicity management for bevacizumab in HHT. MSK, musculoskeletal; MRI, magnetic resonance imaging.
Figure 3.

Approach to dosing, monitoring, and toxicity management for bevacizumab in HHT. MSK, musculoskeletal; MRI, magnetic resonance imaging.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal